More importantly, further experimental investigation should be performed to delineate whether changes in serum me-NAM by inhibiting NNMT activity would improve left ventricular systolic function, and subsequently provide benefits to patients with HF. The gene discussed is NNMT; the disease is hydrops fetalis.